Why the study?
Does the monocyte to high-density lipoprotein cholesterol ratio predict in-hospital and 5-year mortality and MACE in patients with STEMI?
Does the monocyte to high-density lipoprotein cholesterol ratio predict in-hospital and 5-year mortality and MACE in patients with STEMI?
The monocyte to high-density lipoprotein cholesterol ratio (MHR) serves as an independent predictor of short- and long-term mortality and MACE in patients with STEMI, highlighting its potential as a prognostic biomarker.
May aid STEMI risk stratification; hypothesis-generating and requires prospective validation before clinical use.
BACKGROUND: We assessed the value of monocyte to high-density lipoprotein cholesterol ratio (MHR) in predicting in-hospital and 5-year mortality and major adverse cardiovascular events (MACE) in ST-segment elevation myocardial infarction (STEMI) patients. METHODS: A group of 1,598 patients were enrolled and divided into tertiles according to MHR values. The effects of different variables on clinical outcomes were assessed by Cox regression analysis. RESULTS: MHR was found as an independent predictor of in-hospital mortality (HR = 3.745, 95% CI 1.308-5.950), in-hospital MACE (HR 1.501, 95% CI 1.015-1.993, p = 0.022) and 5-year mortality (HR = 2.048, 95% CI 1.225-4.091, p = 0.014) and 5-year MACE (HR 1.285, 95% CI 1.064-1.552, p = 0.009). CONCLUSIONS: MHR is an independent predictor of in-hospital and long term mortality and MACE in STEMI.
No takes yet. Share an insight, caveat, or question.
Açi̇kgöz et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: